We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Renal Cell Carcinoma
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Amougou Boris
Nov 05, 2016
There is some risk to increase the volume of metastatic mass (spine lytic lesion and lung nodule) using sutent. In my point of view its was a good case to purpose him to agree in a trial who assess the impact of usual targeted therapy in non clear cell metastatic renal carcinoma.
Laszlo Torday
Dec 06, 2016
I would be very concerned about the concomittant tretament of this patient with denosumab and sunitinib. Anti-VEGF TKI treatment dramatically increase the freqency of the BRONJ (bisphosphonate related osteonecrosis of the jaw) if the patient is receiving e.g. zoledronic acid. ONJ also a well known side effect of denosumab and denosumab is more potent bone targeting agent than zoledronic acid. There are several reports out there about the interaction of sunitinib and denosumab, and the picture is not worry free... I would also use sunitinib, but with a less potent bisphosphonate like clodronate... And, if applicable, palliatívie radiotherapy to metastatic bone lesions...
zafor masud
Jan 17, 2017
I agree to start with Xgeva and Sutent as recommended at this stage for him with the hope of better control of disease.
sabu john
Jan 19, 2017
Yes I agree
May 06, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Heather
R
Greene
MSN, FNP, AOCNP
Amougou Boris
Nov 05, 2016
Laszlo Torday
Dec 06, 2016
zafor masud
Jan 17, 2017
sabu john
Jan 19, 2017
May 06, 2024
Pending Moderator approval.